Analyst Scoreboard: 5 Ratings For Vericel
Portfolio Pulse from Benzinga Insights
Vericel (NASDAQ:VCEL) has been analyzed by 5 analysts in the last three months, showing unanimous bullish sentiment. The average 12-month price target is $51.6, marking a 10.02% increase from the previous target. Analysts from Truist Securities and HC Wainwright & Co. have raised their price targets, reflecting positive expectations for Vericel's performance. The company, a leader in cell therapy products for sports medicine and severe burn care, shows strong financial health with notable revenue growth, high net margin, and effective debt management.
March 26, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vericel's unanimous bullish ratings from analysts and an increased average price target to $51.6 reflect strong market confidence. The company's robust financial performance and strategic positioning in cell therapy for sports medicine and severe burn care contribute to this positive outlook.
The unanimous bullish sentiment among analysts, coupled with raised price targets, indicates a strong confidence in Vericel's market position and financial health. The company's specialization in cell therapy products for sports medicine and severe burn care, along with its impressive revenue growth and profitability metrics, support a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100